Regulatory Filings • Aug 30, 2021
Regulatory Filings
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 20153-52-2021 |
Data/Ora Ricezione 30 Agosto 2021 09:59:52 |
AIM -Italia/Mercato Alternativo del Capitale |
||
|---|---|---|---|---|
| Societa' | : | MAPS | ||
| Identificativo Informazione Regolamentata |
: | 151372 | ||
| Nome utilizzatore | : | MAPSN03 - Ciscato | ||
| Tipologia | : | REGEM; 3.1 | ||
| Data/Ora Ricezione | : | 30 Agosto 2021 09:59:52 | ||
| Data/Ora Inizio Diffusione presunta |
: | 30 Agosto 2021 09:59:53 | ||
| Oggetto | : | MAPS IS AWARDED THE TENDER CALLED BY EFSA (EUROPEAN FOOD SAFETY AUTHORITY) FOR A TOTAL AMOUNT OF EURO 800 THOUSAND |
||
| Testo del comunicato |
Vedi allegato.
Parma, 30 August 2021
MAPS (MAPS:IM; IT0005364333), an Innovative SME listed on AIM Italia and active in the digital transformation sector, announces that it has been awarded, in a consortium with EcoMole s.r.o., TenWise B.V. and Charité Universitaetsmedizin Berlin, the tender called by the European Food Safety Authority (EFSA) for the automation of the Systematic Review (SR) process of scientific literature using Artificial Intelligence (AI) techniques.
The total amount of the award is Euro 800 thousand, for a duration of four years.
EFSA, the Parma-based Agency set up in 2002 by the European Union, operates independently providing expert advice to enable the European Commission, European Parliament and EU Member States to make effective and timely risk management decisions that ensure the protection of the health of European consumers and the safety of food and the food chain. EFSA's scientific work is used to adopt or revise European legislation, to decide on the approval of regulated substances or to introduce new regulatory frameworks and formulate new policies.
The Authority collects and analyses, using the Systematic Review (SR) methodology, scientific data to ensure that risk assessment at Community level is carried out on the basis of fully comprehensive scientific information. The Systematic Review (SR) is a very rigorous, costly and resource-intensive process. The current methodology is approaching its physical limits as it struggles to cope with the amount of scientific research available today, while this amount is expected to increase significantly in the future.
Maurizio Pontremoli, CEO of MAPS: "We are continuing and extending our collaboration with a client of extremely high standing, as is EFSA. Through this new project we will make a significant contribution to generating benefits in terms of reducing the time and costs associated with the core activity carried out by the Agency. The award of the tender is strategic for us not only because it makes us a candidate to be a player of reference to support EFSA and other European agencies in applying AI technologies in the processing of scientific data, but also because it further qualifies our products that have, at their base, the same technologies that are accredited by this prestigious Agency".
Founded in 2002, MAPS is an Innovative SME operating in the digital transformation sector. With its registered office in Parma and with approximately 200 employees, it produces and distributes software for the analysis of big data that allows client companies to manage and analyse large quantities of data and information, helping them make strategic and operational decisions and define new business models. It operates in a context characterised by high growth potential: the global market for digital transformation technologies reached \$1,100 billion in 2018; in 2020, a market of \$1,600 billion is estimated (CAGR 2018-2020 approximately +20%). MAPS operates through 3 business units (Large Enterprise, Healthcare Industry, Gzoom) and has a portfolio of over 400 highly loyal Customers from different markets: Telco, Utilities, Healthcare, Retail, Industry and Public Administration.
Through the Patient Journey line of products, it is a leader in the sector of patient reception in healthcare facilities, presiding over the market with over 1,300 installations, which manage the access paths of over 20 million patients nationwide. The Group invests constantly in R&D. The Research & Solutions division, established in 2016, is responsible for identifying market needs and developing software solutions.
The Group closed 2020 with consolidated revenues of Euro 17.9 million and an EBITDA of Euro 3.4 million. In the last 3 years, MAPS has tripled revenue from proprietary solutions and more than doubled EBITDA. The company is characterised by high levels of recurring revenues: recurring fee revenues represent 28% of consolidated operating revenues in 2020. The Group's
organic growth has been accompanied by a significant M&A activity, with the acquisition of IG Consulting (2011), Artexe (2018), Roialty (2019), SCS Computers (2020) and IASI (2021).
Release available on and on www.mapsgroup.it
MAPS T +390521052300 [email protected]
Marco Ciscato – Investor Relations Manager [email protected]
NOMAD BPER Banca | T +390272 74 92 29 [email protected]
INVESTOR RELATIONS & FINANCIAL MEDIA IR Top Consulting | T +390245473884 Maria Antonietta Pireddu, [email protected] │ Federico Nasta, [email protected] Domenico Gentile, [email protected] │ Antonio Buozzi, [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.